Signaling in T cells - is anything the m(a)TOR with the picture(s)?

Area of Science:

• Immunology
• Cancer Biology
• Molecular Signaling

Background:

• Checkpoint inhibitors represent a significant advance in cancer therapy, stemming from fundamental research in T-cell signaling.
• Understanding T-cell activation pathways is crucial for improving cancer treatment responsiveness.
• Mammalian (or mechanistic) target of rapamycin (mTOR) pathways play a role in lymphocyte activation.

Purpose of the Study:

• To review key aspects of T-cell signaling pathways relevant to cancer immunotherapy.
• To critically examine current models of T-cell signaling, particularly involving mTOR.
• To identify future research directions for enhancing cancer treatment efficacy.

Main Methods:

• Review and synthesis of existing literature on T-cell signaling over approximately 30 years.
• Focus on canonical T-cell signaling and the role of mTOR pathways.
• Critical analysis of current models and identification of knowledge gaps.

Main Results:

• T-cell signaling research has paved the way for successful immunotherapies.
• Existing models of T-cell signaling, including mTOR, require further refinement.
• Disparities in findings necessitate attention to temporal, spatial, and stochastic aspects.

Conclusions:

• Continued investment in basic T-cell signaling research is vital for advancing cancer therapy.
• Addressing complexities and inconsistencies in signaling pathways will drive future therapeutic successes.
• Future progress requires a deeper understanding of the dynamic nature of T-cell responses.